Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors
2009

Iodine Atoms: A New Feature for Designing Transthyretin Inhibitors

publication Evidence: moderate

Author Information

Author(s): Mairal Teresa, Nieto Joan, Pinto Marta, Almeida Maria Rosário, Gales Luis, Ballesteros Alfredo, Barluenga José, Pérez Juan J., Vázquez Jesús T., Centeno Nuria B., Saraiva Maria Joao, Damas Ana M., Planas Antoni, Arsequell Gemma, Valencia Gregorio

Primary Institution: Institut de Química Avançada de Catalunya, I.Q.A.C.-C.S.I.C., Barcelona, Spain

Hypothesis

Can adding iodine atoms to known transthyretin inhibitors create more effective drugs?

Conclusion

The study found that iodine atoms significantly enhance the potency of transthyretin fibrillogenesis inhibitors.

Supporting Evidence

  • Iodine atoms can enhance the binding affinity of drugs to transthyretin.
  • The study tested various iodinated analogues of diflunisal.
  • Iodinated compounds showed improved inhibition of fibrillogenesis compared to non-iodinated versions.
  • The presence of iodine correlated with increased potency in inhibiting amyloid formation.

Takeaway

This research shows that adding iodine to certain drugs can make them better at stopping a harmful protein from forming clumps in the body.

Methodology

The study involved designing and testing iodinated analogues of known transthyretin inhibitors and assessing their effectiveness in inhibiting fibrillogenesis.

Limitations

Further preclinical tests are needed to validate these compounds as potential drugs for TTR-related amyloidosis.

Digital Object Identifier (DOI)

10.1371/journal.pone.0004124

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication